Menjugate

N. meningitidis Group C (Strain C11) oligosaccharide conjugated to Corynebacterium diphtheriae CRM197, the active ingredient in Menjugate, is a vaccine presented as an injectable solution for intramuscular use. It prevents invasive disease caused by Neisseria meningitidis serogroup C in individuals at risk.

GNH USA supplies Menjugate as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menjugate is a conjugate vaccine that targets Neisseria meningitidis serogroup C to provide active immunity. - Invasive meningococcal disease (serogroup C): reduces the risk of meningitis and septicemia caused by the bacterium. - Outbreak control: helps limit the spread of serogroup C disease in community or institutional settings. - Travel to endemic regions: offers protection for travelers who may be exposed to serogroup C meningococcus.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness: localized erythema around the injection area. - Swelling: transient edema at the site of administration. - Fever: low‑grade temperature rise within 24‑48 hours. - Headache: mild headache following vaccination. - Malaise: general feeling of fatigue or unease.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Seizure: rare occurrence of convulsive activity post‑vaccination. - Guillain‑Barré syndrome: extremely rare autoimmune neuropathy. - Severe allergic reaction: includes angioedema or bronchospasm. - Immune‑mediated thrombocytopenia: very rare drop in platelet count.

Before administering Menjugate, consider the following precautions. - Allergy assessment: avoid in persons with known hypersensitivity to any vaccine component. - Pregnancy: use only if the expected benefit outweighs potential risk; consult a healthcare professional. - Immunocompromised patients: vaccine may be less effective; monitor immune response. - Concurrent vaccines: may be given with other vaccines at separate anatomical sites. - Age restrictions: approved for individuals meeting age criteria defined by local health authorities. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menjugate may interact with other agents; monitor as indicated. Major Interactions (Avoid): - Live bacterial vaccines: co‑administration may alter immune response. - Immunoglobulin therapy: can reduce vaccine efficacy. Moderate Interactions (Monitor Closely): - Antipyretics: may mask post‑vaccination fever. - Immunosuppressive drugs: may diminish antibody production. - Blood products: may interfere with serologic testing for vaccine response.